
Gender Diversity In Leadership - How Does Biopharma Compare?
How the 10 largest publicly traded biopharmaceutical companies compare to 10 of the largest publicly traded nonbiopharmaceutical companies in the area of gender diversity among executive leadership.
Continue Reading..

Is It Time For Branded Biopharmaceuticals To Get Into The Business Of Generics?
With President Trump’s recently announced focus on reducing the price of prescription drugs, perhaps it is time branded biopharmaceutical companies consider competing in other areas beyond just biosimilars (i.e., generic biologics).
Continue Reading..

Does Drug Development Require A Passionate Commitment?
Successful drug discovery and development requires a passionate commitment, something that can only be displayed during the breakout sessions at the J.P. Morgan annual healthcare conference.
Continue Reading..

JPM — More Than A Gap In Gender
While some continue to focus on the lack of gender diversity at the annual J.P. Morgan healthcare conference, GSK’s CEO, Emma Walmsley, notes that supporting diversity means doing more than just focusing on the “gender agenda.”
Continue Reading..

Connectivity — The Beauty Of JPM And BTS
The annual J.P. Morgan and Biotech Showcase conferences not only provide great networking opportunities, they expose you to interesting and cutting-edge companies to keep on your radar.
Continue Reading..

Can JPM And BTS Make A Bigger Difference?
An idea for how the biopharmaceutical and life science industries could make a bigger difference during the annual January JPM invasion of San Francisco.
Continue Reading..

How Will You Respond When Social Media Targets Your Company — Or You?
Important lessons learned from the 2014 #SaveJosh social media firestorm that engulfed Chimerix, as well as the company’s former CEO, Ken Moch.
Continue Reading..

A Behind The Scenes Look Into Planning For BIO 2018 — Thus Far
A behind the scenes look into the educational planning for the 2018 BIO International Convention in Boston.
Continue Reading..

Will Neuroscience R&D Be The Next Big Thing — Again?
Merck’s VP and head of neuroscience research, Darryle Schoepp, shares insight as to why there is increased interest in developing therapeutics targeting neurodegenerative diseases.
Continue Reading..

What Kinds Of Deals To Expect At JPM In 2018
Merck’s SVP of BD and licensing, Ben Thorner, provides insight into what type of deals to expect at the 36th Annual J.P. Morgan Healthcare Conference.
Continue Reading..
This website uses cookies to ensure you get the best experience on our website. Learn more